|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; and National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grossman SA, Ye X, Piantadosi S, Desideri
S, Nabors LB, Rosenfeld M and Fisher J: NABTT CNS Consortium:
Survival of patients with newly diagnosed glioblastoma treated with
radiation and temozolomide on research studies in the United
States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hou LC, Veeravagu A, Hsu AR and Tse VC:
Recurrent glioblastoma multiforme: A review of natural history and
management options. Neurosurg Focus. 20:E52006.PubMed/NCBI
|
|
4
|
Wong ET, Hess KR, Gleason MJ, Jaeckle KA,
Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and
prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol. 17:2572–2578. 1999.PubMed/NCBI
|
|
5
|
Lamborn KR, Yung WK, Chang SM, Wen PY,
Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink
KL, et al: North American Brain Tumor Consortium: Progression-free
survival: An important end point in evaluating therapy for
recurrent high-grade gliomas. Neuro Oncol. 10:162–170. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang W, Zhang J, Yan W, You G, Bao Z, Li
S, Kang C, Jiang C, You Y, Zhang Y, et al: Whole-genome microRNA
expression profiling identifies a 5-microRNA signature as a
prognostic biomarker in Chinese patients with primary glioblastoma
multiforme. Cancer. 119:814–824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Knott JC, Mahesparan R, Garcia-Cabrera I,
Bølge Tysnes B, Edvardsen K, Ness GO, Mørk S, Lund-Johansen M and
Bjerkvig R: Stimulation of extracellular matrix components in the
normal brain by invading glioma cells. Int J Cancer. 75:864–872.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Freije WA, Castro-Vargas FE, Fang Z,
Horvath S, Cloughesy T, Liau LM, Mischel PS and Nelson SF: Gene
expression profiling of gliomas strongly predicts survival. Cancer
Res. 64:6503–6510. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Phillips HS, Kharbanda S, Chen R, Forrest
WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et
al: Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berens ME and Giese A: ‘…those left
behind.’ Biology and oncology of invasive glioma cells. Neoplasia.
1:208–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Besse A, Sana J, Fadrus P and Slaby O:
MicroRNAs involved in chemo- and radioresistance of high-grade
gliomas. Tumour Biol. 34:1969–1978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: MicroRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin AA, Zhang LH, Cheng JX, Dong Y, Liu
BL, Han N and Zhang X: The predictive but not prognostic value of
MGMT promoter methylation status in elderly glioblastoma patients:
A meta-analysis. PLoS One. 9:e851022014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colen RR, Vangel M, Wang J, Gutman DA,
Hwang SN, Wintermark M, Jain R, Jilwan-Nicolas M, Chen JY, Raghavan
P, et al: TCGA Glioma Phenotype Research Group: Imaging genomic
mapping of an invasive MRI phenotype predicts patient outcome and
metabolic dysfunction: A TCGA glioma phenotype research group
project. BMC Med Genomics. 7:302014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiagen: Glioma Copy Number PCR Array.
http://www.sabiosciences.com/copynumber_product/HTML/VAHS-0053Z.html
|
|
16
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WB, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropatho. 114:97–109. 2007. View Article : Google Scholar
|
|
17
|
Jolliffe IT: Springer Series in
Statistics: Principal Component Analysis. (2nd). (NY). Springer.
282002. ISBN: 978-0-387-95442-4
|
|
18
|
Ohgaki H and Kleihues P: The definition of
primary and secondary glioblastoma. Clin Cancer Res. 19:764–772.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moh MC and Shen S: The roles of cell
adhesion molecules in tumor suppression and cell migration: A new
paradox. Cell Adhes Migr. 3:334–336. 2009. View Article : Google Scholar
|
|
20
|
Huang S, Chen Y, Wu W, Ouyang N, Chen J,
Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast
cancer growth and malignant behavior by targeting the pro-apoptotic
purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Caramuta S, Lee L, Ozata DM, Akçakaya P,
Georgii-Hemming P, Xie H, Amini RM, Lawrie CH, Enblad G, Larsson C,
et al: Role of microRNAs and microRNA machinery in the pathogenesis
of diffuse large B-cell lymphoma. Blood Cancer J. 3:e1522013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W
and Yang Z: MiR-328 expression is decreased in high-grade gliomas
and is associated with worse survival in primary glioblastoma. PLoS
One. 7:e472702012. View Article : Google Scholar : PubMed/NCBI
|
